Skip to main content
. Author manuscript; available in PMC: 2009 Feb 16.
Published in final edited form as: N Engl J Med. 2008 Mar 12;358(15):1560–1571. doi: 10.1056/NEJMoa0800260

Table 5. Serious Adverse Events.*.

Event Acyclovir Group
(N = 400)
Placebo Group
(N = 421)
no. (%)
Total no. of events 49 46
Participants with ≥1 event 44 (11.0) 42 (10.0)
Death 1 (0.2) 1 (0.2)
Life-threatening illness 6 (1.5) 8 (1.9)
Hospitalization 38 (9.5) 34 (8.1)
Persistent disability 0 1 (0.2)
Congenital abnormality 0 0
*

See the Supplementary Appendix for details.